Drug intelligence / Profile preview

NW-8-256

Development stage: Preclinical
Lead developer: Newave Pharmaceutical
Modality: Small Molecules

Overview

NW-8-256 is a preclinical diagnostic agent developed by Newave Pharmaceutical. It is specifically designed to target the BTK-F107C/C mutation, a variant of Bruton's tyrosine kinase (BTK) associated with hematological malignancies. The agent likely functions as a mutation-specific probe or tracer to detect the presence of this specific BTK variant, aiding in the diagnosis, stratification, or monitoring of patients with B-cell cancers who may be resistant to standard BTK inhibitors.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on NW-8-256.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW-8-256.